Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor therapy.